CA
NZ
UK
AU
IND
US
Total revenue was USD 65.414 million, against USD 56.425 million a year earlier. Management attributed the change to higher royalty revenue from Eli Lilly, increased Rayaldee sales and growth in international operations. For the nine months, revenue was USD 206.456 million, against USD 159.239 …
Total revenues were USD 275.1 million, up 10.2% from USD 249.7 million. Energy Storage revenue was USD 49.9 million against USD 20.4 million, which the company attributed to high asset availability, merchant pricing in the PJM market and capacity added over the past 12 …
Total investment income was USD 341.3 million against USD 322.6 million a year earlier. Interest income from investments was USD 283.4 million and payment-in-kind interest income was USD 24.9 million, whileDividendincome was USD 15.7 million against USD 6.0 million. The company linked higher interest …
Consumable revenue was USD 20.8 million against USD 21.3 million a year earlier. Instrument revenue was USD 13.2 million against USD 11.3 million, and service and other revenue was USD 6.6 million against USD 5.8 million. The company placed 15 Revio systems against 13, …
Animal Health net sales were USD 293.0 million, against USD 283.5 million, and the segment's adjusted EBITDA was USD 73.9 million, against USD 74.9 million. Sales of medicated feed additives and other products rose to USD 206.5 million from USD 195.2 million, which management …
TheCash Flow Statementshows how theBalance Sheetchanged. Over nine months, Paycom borrowed USD 900.0 million under itsCreditfacility, repaid USD 150.0 million and repurchased common stock for USD 1,390.9 million, against USD 218.9 million in the same period of 2025. Long-termDebtwas USD 750.0 million at September …
The company attributed the warrant decrease primarily to lower common stock and public warrant values and a shorter remaining term to expiration. A year earlier, the same line showed a USD 23.75 million decrease. The warrants were extended in 2026 and now expire on …
Management said the OPUS-1 trial enrolled 3,572 adults aged 50 and older, plus 475 adults aged 18 to 49, and compared VAX-31 head to head with PCV20 and PCV21. The company reported that VAX-31 met all prespecified primary endpoints. All 28 serotypes shared with …
The company stated that the majority of its future revenues for the foreseeable future come from Papzimeos sales as commercial activities expand. It said its transition to sustained profitability depends on continued commercialization of Papzimeos and potential commercialization of other candidates. It reported profitability …
The company had 607 fertility and family building clients at September 30, 2026, against 553 a year earlier. Average members were 7,176,000 in the quarter, against 6,757,000. Management said the majority of the new clients and lives are stated to go live in the …
Please wait processing your request...